CORRELATION BETWEEN PERIPHERAL BLOOD BIOMARKERS AND CLINICAL EFFICACY OF PD-1/PD-L1 INHIBITORS IN THE TREATMENT OF CHOLANGIOCARCINOMA

Fanli Zeng, Donghe Wang, Heqing Yang^* 

Department of General Surgery, The Second Hospital of Qinhuangdao, Qinhuangdao 066600, PR China

Objective: Investigating the effect of PD-1/PD-L1 inhibitors on peripheral blood biological indexes of cholangiocarcinoma and determining its correlation with the clinical efficacy of cholangiocarcinoma. 

Methods: A total of 98 cholangiocarcinoma patients (diagnosed by pathological examination from May 2017 to May 2019) were selected as subjects of this study. According to their recovery prognosis, participants were divided into a good prognosis group (Group A) and a poor prognosis group (Group B), with 49 cases in each group. General data for the two groups were compared and the changes of peripheral cytokines (before and after treatment) were determined. In addition, the clinical efficacy of the two groups was established and the correlation between peripheral cytokines and clinical efficacy was analysed. 

Results: IFN-γ in group B after treatment, TNF- α, The concentrations of IL-6, IL-7, FGF and G-CSF in Group B were significantly lower than that of Group A (P<0.05). The effective rate of clinical efficacy in Group B was 79.59% (39/49), which was significantly better (P<0.05) than the 42.86% (21/49) of Group A. The clinical efficacy of Group B was correlated with IL-6, IL-7, FGF and G-CSF (P<0.05) and the AUC values of IL-6, IL-7, basic FGF and G-CSF were 0.829, 0.815, 0.856 and 0.614 respectively (with the AUC value of basic FGF being the largest). These factors could effectively diagnose the relationship between basic FGF and the clinical efficacy of cholangiocarcinoma.

Conclusion: PD-1/PD-L1 inhibitors affect the peripheral cytokines of patients with cholangiocarcinoma. By observing the changes in the concentrations of IL-6, IL-7, FGF and G-CSF, the clinical efficacy of patients could be estimated – providing a reference basis for clinical rational drug use, and helping the patients to receive the best benefit.